Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality

Susan Olender(Columbia University Irving Medical Center), Marta Boffito(Chelsea and Westminster Hospital NHS Foundation Trust), Anu Osinusi(Gilead Sciences (United States)), Bindu Balani(Association Clinique et Thérapeutique Infantile du Val de Marne), Dax Kurbegov(Sarah Cannon), Kathleen M. Mullane(Karolinska University Hospital), Richard Haubrich(University of California San Diego), Anand P. Chokkalingam(Berkeley Public Health Division), Parag Goyal(Cornell University), David Chien Lye(Agency for Science, Technology and Research), Antonella Castagna(Vita-Salute San Raffaele University), Helena Díaz-Cuervo(Gilead Sciences (Spain)), Lanjia Lin(Gilead Sciences (United States)), I‐Heng Lee(Gilead Sciences (United States)), Francesco Giuseppe De Rosa(University of Turin), Raffaele Bruno(University of Pavia), George Y. Wu(University of Chicago), Estebán Martínez(Instituto de Salud Carlos III), Shin‐Woo Kim(Hankuk University of Foreign Studies), Hao Hu(Xi'an University of Architecture and Technology), Theresa L. Walunas(Northwestern University), Su Wang(Rutgers, The State University of New Jersey), Diego Ripamonti(Ospedale Papa Giovanni XXIII), Katherine K Perez(Houston Methodist), Diana M. Brainard(Gilead Sciences (United States)), José Ignacio Bernardino(Hospital Universitario La Paz), George Diaz(Providence Regional Medical Center Everett), Robert Gottlieb(Baylor University Medical Center)

Open Forum Infectious Diseases

May 26, 2021

Cited by 45

|New England Journal of Medicine|2020|2.4k

|New England Journal of Medicine|2013|1.8k

|Proceedings of the National Academy of Sciences|2009|1.4k

|New England Journal of Medicine|2017|1.2k

|New England Journal of Medicine|2013|1.1k

Related Papers